BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the bioequivalence and the within-subject variability
between the test formulation of extended-release tablet of cilostazol (PMR) administered once
daily and the reference formulation of immediate- release tablet of cilostazol (Cilostazol)
administered twice-daily in normal healthy male and female subjects under fasting conditions.